Maze Therapeutics (MAZE) EPS (Basic) (2024 - 2026)

Maze Therapeutics has reported EPS (Basic) for 3 years, with the latest figure at -$0.36 in Q1 2026.

• Quarterly EPS (Basic) rose 68.25% year-over-year to -$0.36 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$1.68 (down 214.55% YoY) and the FY2025 annual result came in at -$3.05, down 314.7% from the prior year.
• EPS (Basic) slipped to -$0.36 in Q1 2026 per MAZE's latest filing, from -$0.16 in the prior quarter.
• Over five years, EPS (Basic) peaked at $58.2 in Q2 2024 and troughed at -$16.54 in Q4 2024.
• A 3-year average of $1.83 and a median of -$0.77 in 2025 frame the typical range for EPS (Basic).
• The widest YoY moves for EPS (Basic): up 99.01% in 2025, down 101.32% in 2025.
• Over 3 years, EPS (Basic) stood at -$16.54 in 2024, then soared by 99.01% to -$0.16 in 2025, then tumbled by 122.16% to -$0.36 in 2026.
• According to Business Quant data, EPS (Basic) over the past three periods registered -$0.36, -$0.16, and -$0.66 for Q1 2026, Q4 2025, and Q3 2025 respectively.